{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:13:18Z","timestamp":1793945598952,"version":"4.8.0"},"reference-count":156,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)\u2013containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL\/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL\/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL\/SLL and Richter transformation.<\/jats:p>","DOI":"10.6004\/jnccn.2026.0012","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:34Z","timestamp":1773318694000},"page":"68-80","source":"Crossref","is-referenced-by-count":9,"title":["NCCN Guidelines\u00ae Insights: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 2.2026"],"prefix":"10.6004","volume":"24","author":[{"given":"William G.","family":"Wierda","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brown","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Bociek","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Boyer","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cortese","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Cripe","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"D\u2019Angelo","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Darnell","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall S.","family":"Davis","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Eradat","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem","family":"Esteghamat","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Gaballa","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Huntington","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio A.","family":"Mosse","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Nakhoda","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Riedell","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Schorr","sequence":"additional","affiliation":[{"name":"Patient Advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Schuster","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"Seshadri","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tait","family":"Shanafelt","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sitlinger","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Thompson","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Dwyer","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Sundar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Proc Natl Acad Sci U S A","first-page":"21194","article-title":"High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment","volume":"108","author":"Logan AC","year":"2011","unstructured":"Logan AC, Gao H, Wang C,  High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A 2011;108:21194\u201321199."},{"key":"B2","series-title":"Leukemia","first-page":"929","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron AC","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A,  A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 2016;30:929\u2013936."},{"key":"B3","series-title":"Leuk Lymphoma","first-page":"1986","article-title":"Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry","volume":"59","author":"Aw A","year":"2018","unstructured":"Aw A, Kim HT, Fernandes SM,  Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. Leuk Lymphoma 2018;59:1986\u20131989."},{"key":"B4","series-title":"Blood","first-page":"1951","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson PA","year":"2019","unstructured":"Thompson PA, Srivastava J, Peterson C,  Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 2019;134:1951\u20131959."},{"key":"B5","series-title":"Leukemia","first-page":"142","article-title":"Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron AC","year":"2013","unstructured":"Rawstron AC, Bottcher S, Letestu R,  Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013;27:142\u2013149."},{"key":"B6","series-title":"Br J Haematol","first-page":"360","article-title":"Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR","volume":"166","author":"Raponi S","year":"2014","unstructured":"Raponi S, Della Starza I, De Propris MS,  Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol 2014;166:360\u2013368."},{"key":"B7","series-title":"Cytometry B Clin Cytom","first-page":"121","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project","volume":"94","author":"Rawstron AC","year":"2018","unstructured":"Rawstron AC, Kreuzer KA, Soosapilla A,  Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom 2018;94:121\u2013128."},{"key":"B8","series-title":"Leukemia","first-page":"3059","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda WG","year":"2021","unstructured":"Wierda WG, Rawstron A, Cymbalista F,  Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia 2021;35:3059\u20133072."},{"key":"B9","series-title":"N Engl J Med","first-page":"1177","article-title":"Measurable residual disease-guided therapy for chronic lymphocytic leukemia","volume":"393","author":"Munir T","year":"2025","unstructured":"Munir T, Girvan S, Cairns DA,  Measurable residual disease-guided therapy for chronic lymphocytic leukemia. N Engl J Med 2025;393:1177\u20131190."},{"key":"B10","series-title":"J Clin Oncol","first-page":"788","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naive chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids MS","year":"2025","unstructured":"Davids MS, Ryan CE, Lampson BL,  Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naive chronic lymphocytic leukemia population enriched for high-risk disease. J Clin Oncol 2025;43:788\u2013799."},{"key":"B11","series-title":"J Clin Oncol","first-page":"2409","article-title":"Zanubrutinib and venetoclax for patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del(17p)\/TP53 mutation: SEQUOIA Arm D results","volume":"43","author":"Shadman M","year":"2025","unstructured":"Shadman M, Munir T, Ma S,  Zanubrutinib and venetoclax for patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del(17p)\/TP53 mutation: SEQUOIA Arm D results. J Clin Oncol 2025;43:2409\u20132417."},{"key":"B12","series-title":"Blood","first-page":"3226","article-title":"Compartment effect on the prognostic significance of MRD detection in CLL: impact of treatment type and duration of follow-up","volume":"128","author":"Rawstron AC","year":"2016","unstructured":"Rawstron AC, Howard D, McParland L,  Compartment effect on the prognostic significance of MRD detection in CLL: impact of treatment type and duration of follow-up. Blood 2016;128:3226."},{"key":"B13","series-title":"Hemasphere","first-page":"e287","article-title":"Minimal residual disease assessment in CLL: ready for use in clinical routine?","volume":"3","author":"F\u00fcrstenau M","year":"2019","unstructured":"F\u00fcrstenau M, De Silva N, Eichhorst B, Hallek M. Minimal residual disease assessment in CLL: ready for use in clinical routine? Hemasphere 2019;3:e287."},{"key":"B14","series-title":"Blood","first-page":"1924","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf O","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C,  Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood 2024;144:1924\u20131935."},{"key":"B15","series-title":"Blood","first-page":"839","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour JF","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF,  Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood 2022;140:839\u2013850."},{"key":"B16","series-title":"J Clin Oncol","first-page":"3689","article-title":"Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib- venetoclax versus chlorambucil-obinutuzumab in the GLOW study","volume":"41","author":"Munir T","year":"2023","unstructured":"Munir T, Moreno C, Owen C,  Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib- venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J Clin Oncol 2023;41:3689\u20133699."},{"key":"B17","series-title":"Blood","first-page":"Abstract 1871","article-title":"First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): GLOW study 64-month follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis","volume":"144","author":"Niemann CU","year":"2024","unstructured":"Niemann CU, Munir T, Owen C,  First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): GLOW study 64-month follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis. Blood 2024;144(Suppl 1):Abstract 1871."},{"key":"B18","series-title":"NEJM Evid","first-page":"EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater AP","year":"2022","unstructured":"Kater AP, Owen C, Moreno C,  Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 2022;1:EVIDoa2200006."},{"key":"B19","series-title":"N Engl J Med.","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","author":"Al-Sawaf O","unstructured":"Al-Sawaf O, Stumpf J, Zhang C,  Fixed-duration versus continuous treatment for chronic lymphocytic leukemia. N Engl J Med. Published online December 6, 2025. doi: 10.1056\/NEJMoa2515458"},{"key":"B20","series-title":"Clin Cancer Res","first-page":"2593","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan JN","year":"2023","unstructured":"Allan JN, Flinn IW, Siddiqi T,  Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia. Clin Cancer Res 2023;29:2593\u20132601."},{"key":"B21","series-title":"J Clin Oncol","first-page":"Abstract 7036","article-title":"Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study","volume":"43","author":"Ghia P","year":"2025","unstructured":"Ghia P, Barr PM, Allan JN,  Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. J Clin Oncol 2025;43(Suppl):Abstract 7036."},{"key":"B22","series-title":"N Engl J Med","first-page":"748","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown JR","year":"2025","unstructured":"Brown JR, Seymour JF, Jurczak W,  Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med 2025;392:748\u2013762."},{"key":"B23","series-title":"Blood","first-page":"Abstract 585","article-title":"IGHV unmutated status, low tumor lysis risk disease and BRAF mutated status are predictors for early MRD responders treated with MRD defined ibrutinib with venetoclax: report of the UK NCRI FLAIR study","volume":"144","author":"Munir T","year":"2024","unstructured":"Munir T, Varghese AM, Bloor A,  IGHV unmutated status, low tumor lysis risk disease and BRAF mutated status are predictors for early MRD responders treated with MRD defined ibrutinib with venetoclax: report of the UK NCRI FLAIR study. Blood 2024;144(Suppl 1):Abstract 585."},{"key":"B24","series-title":"N Engl J Med","first-page":"2517","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach JA","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA,  Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379:2517\u20132528."},{"key":"B25","series-title":"Blood","first-page":"2810","article-title":"Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib","volume":"138","author":"Wang XV","year":"2021","unstructured":"Wang XV, Hanson CA, Tschumper RC,  Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood 2021;138:2810\u20132827."},{"key":"B26","series-title":"Haematologica","first-page":"2108","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno C","year":"2022","unstructured":"Moreno C, Greil R, Demirkan F,  First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica 2022;107:2108\u20132120."},{"key":"B27","series-title":"Leukemia","first-page":"1171","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman JP","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W,  Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia 2022;36:1171\u20131175."},{"key":"B28","series-title":"Blood","first-page":"1276","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman JP","year":"2025","unstructured":"Sharman JP, Egyed M, Jurczak W,  Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood 2025;146:1276\u20131285."},{"key":"B29","series-title":"J Clin Oncol","first-page":"3441","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P,  Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021;39:3441\u20133452."},{"key":"B30","series-title":"N Engl J Med","first-page":"319","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown JR","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P,  Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319\u2013332."},{"key":"B31","series-title":"Lancet Oncol","first-page":"744","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"Furstenau M","year":"2024","unstructured":"Furstenau M, Kater AP, Robrecht S,  First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2024;25:744\u2013759."},{"key":"B32","series-title":"J Clin Oncol","first-page":"2841","article-title":"Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman JP","year":"2025","unstructured":"Sharman JP, Munir T, Grosicki S,  Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol 2025;43:2841\u20132549."},{"key":"B33","series-title":"Blood","first-page":"Abstract 4633","article-title":"Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL\/small lymphocytic lymphoma (SLL): updated follow-up of TRANSCEND CLL 004","volume":"144","author":"Siddiqi T","year":"2024","unstructured":"Siddiqi T, Gauthier J, Kenderian SS,  Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL\/small lymphocytic lymphoma (SLL): updated follow-up of TRANSCEND CLL 004. Blood 2024;144(Suppl 1):Abstract 4633."},{"key":"B34","series-title":"Blood","first-page":"Abstract 887","article-title":"Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): primary results from the open-label, phase 1\/2 Transcend CLL 004 study","volume":"144","author":"Wierda WG","year":"2024","unstructured":"Wierda WG, Dorritie K, Gauthier J,  Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): primary results from the open-label, phase 1\/2 Transcend CLL 004 study. Blood 2024;144(Suppl 1):Abstract 887."},{"key":"B35","series-title":"J Clin Oncol","first-page":"2343","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou AM","year":"2006","unstructured":"Tsimberidou AM, O\u2019Brien S, Khouri I,  Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006;24:2343\u20132351."},{"key":"B36","series-title":"Haematologica","first-page":"765","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang Y","year":"2020","unstructured":"Wang Y, Tschautscher MA, Rabe KG,  Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica 2020;105:765\u2013773."},{"key":"B37","series-title":"Leukemia","first-page":"169","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf O","year":"2021","unstructured":"Al-Sawaf O, Robrecht S, Bahlo J,  Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia 2021;35:169\u2013176."},{"key":"B38","series-title":"Ann Hematol","first-page":"2513","article-title":"Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair R","year":"2021","unstructured":"Elnair R, Ellithi M, Kallam A,  Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database. Ann Hematol 2021;100:2513\u20132519."},{"key":"B39","series-title":"Blood Cancer J","first-page":"23","article-title":"Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL","volume":"15","author":"Kittai AS","year":"2025","unstructured":"Kittai AS, Huang Y, Miller S,  Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J 2025;15:23."},{"key":"B40","series-title":"Am J Surg Pathol","first-page":"1605","article-title":"IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao Z","year":"2007","unstructured":"Mao Z, Quintanilla-Martinez L, Raffeld M,  IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 2007;31:1605\u20131614."},{"key":"B41","series-title":"Blood","first-page":"3391","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi D","year":"2011","unstructured":"Rossi D, Spina V, Deambrogi C,  The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117:3391\u20133401."},{"key":"B42","series-title":"Br J Haematol","first-page":"854","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta P","year":"2020","unstructured":"Abrisqueta P, Delgado J, Alcoceba M,  Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol 2020;190:854\u2013863."},{"key":"B43","series-title":"Br J Haematol","first-page":"1016","article-title":"Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome","volume":"198","author":"Favini C","year":"2022","unstructured":"Favini C, Talotta D, Almasri M,  Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. Br J Haematol 2022;198:1016\u20131022."},{"key":"B44","series-title":"Nat Med","first-page":"158","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry EM","year":"2023","unstructured":"Parry EM, Leshchiner I, Guieze R,  Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med 2023;29:158\u2013169."},{"key":"B45","series-title":"Nat Commun","first-page":"309","article-title":"Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis","volume":"14","author":"Broseus J","year":"2023","unstructured":"Broseus J, Hergalant S, Vogt J,  Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis. Nat Commun 2023;14:309."},{"key":"B46","series-title":"Blood Adv","first-page":"2773","article-title":"Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review","volume":"9","author":"Barrett A","year":"2025","unstructured":"Barrett A, Harris C, Eyre TA. Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review. Blood Adv 2025;9:2773\u20132780."},{"key":"B47","series-title":"J Nucl Med","first-page":"1267","article-title":"Detection of Richter\u2019s transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi JF","year":"2006","unstructured":"Bruzzi JF, Macapinlac H, Tsimberidou AM,  Detection of Richter\u2019s transformation of chronic lymphocytic leukemia by PET\/CT. J Nucl Med 2006;47:1267\u20131273."},{"key":"B48","series-title":"Ann Oncol","first-page":"508","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy A","year":"2009","unstructured":"Noy A, Schoder H, Gonen M,  The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009;20:508\u2013512."},{"key":"B49","series-title":"Leuk Lymphoma","first-page":"314","article-title":"2-[18F]fluoro-2-deoxy-D- glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","volume":"55","author":"Papajik T","year":"2014","unstructured":"Papajik T, Myslivecek M, Urbanova R,  2-[18F]fluoro-2-deoxy-D- glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. Leuk Lymphoma 2014;55:314\u2013319."},{"key":"B50","series-title":"Blood","first-page":"2783","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi L","year":"2014","unstructured":"Falchi L, Keating MJ, Marom EM,  Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 2014;123:2783\u20132790."},{"key":"B51","series-title":"Leuk Lymphoma","first-page":"1474","article-title":"An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter\u2019s syndrome","volume":"57","author":"Michallet AS","year":"2016","unstructured":"Michallet AS, Sesques P, Rabe KG,  An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter\u2019s syndrome. Leuk Lymphoma 2016;57:1474\u20131477."},{"key":"B52","series-title":"Am J Hematol","first-page":"56","article-title":"Patient characteristics that predict Richter\u2019s transformation in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"98","author":"Kittai AS","year":"2023","unstructured":"Kittai AS, Huang Y, Beckwith KA,  Patient characteristics that predict Richter\u2019s transformation in patients with chronic lymphocytic leukemia treated with ibrutinib. Am J Hematol 2023;98:56\u201365."},{"key":"B53","series-title":"Haematologica","first-page":"2258","article-title":"Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy","volume":"104","author":"Mato AR","year":"2019","unstructured":"Mato AR, Wierda WG, Davids MS,  Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica 2019;104:2258\u20132264."},{"key":"B54","series-title":"Haematologica","first-page":"240564","article-title":"The role of 18F-FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor","volume":"105","author":"Wang Y","year":"2020","unstructured":"Wang Y, Rabe KG, Bold MS,  The role of 18F-FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica 2020;105:240564."},{"key":"B55","series-title":"Blood","first-page":"3419","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding W","year":"2017","unstructured":"Ding W, LaPlant BR, Call TG,  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 2017;129:3419\u20133427."},{"key":"B56","series-title":"Br J Haematol","first-page":"363","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre","volume":"185","author":"Rogers KA","year":"2019","unstructured":"Rogers KA, Huang Y, Dotson E,  Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. Br J Haematol 2019;185:363\u2013366."},{"key":"B57","series-title":"Br J Haematol","first-page":"e117","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand P","year":"2020","unstructured":"Armand P, Murawski N, Molin D,  Pembrolizumab in relapsed or refractory Richter syndrome. Br J Haematol 2020;190:e117\u2013120."},{"key":"B58","series-title":"Blood Adv","first-page":"1958","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain N","year":"2023","unstructured":"Jain N, Senapati J, Thakral B,  A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 2023;7:1958\u20131966."},{"key":"B59","series-title":"J Clin Oncol","first-page":"Abstract 7050","article-title":"Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL)","volume":"42","author":"Wang Y","year":"2024","unstructured":"Wang Y, LaPlant BR, Parikh SA,  Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL). J Clin Oncol 2024;42(Suppl):Abstract 7050."},{"key":"B60","series-title":"Blood","first-page":"Abstract 90","article-title":"Correlates of response to combined checkpoint and BTK inhibition for treatment of Richter transformation: extended follow-up from the prospective RT1 trial","volume":"146","author":"Al-Sawaf O","year":"2025","unstructured":"Al-Sawaf O, Robrecht S, Giza A,  Correlates of response to combined checkpoint and BTK inhibition for treatment of Richter transformation: extended follow-up from the prospective RT1 trial. Blood 2025;146(Suppl 1):Abstract 90."},{"key":"B61","series-title":"Lancet Oncol","first-page":"1298","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi A","year":"2024","unstructured":"Tedeschi A, Frustaci AM, Condoluci A,  Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2024;25:1298\u20131309."},{"key":"B62","series-title":"Lancet Haematol","first-page":"e912","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1\u20132 study","volume":"8","author":"Eyre TA","year":"2021","unstructured":"Eyre TA, Schuh A, Wierda WG,  Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1\u20132 study. Lancet Haematol 2021;8:e912\u2013921."},{"key":"B63","series-title":"Lancet Haematol","first-page":"e682","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study","volume":"11","author":"Wierda WG","year":"2024","unstructured":"Wierda WG, Shah NN, Cheah CY,  Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study. Lancet Haematol 2024;11:e682\u2013692."},{"key":"B64","series-title":"Blood","first-page":"Abstract 1017","article-title":"Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b\/2 EPCORE CLL-1 trial","volume":"146","author":"Kater A","year":"2025","unstructured":"Kater A, Janssens A, Eradat H,  Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b\/2 EPCORE CLL-1 trial. Blood 2025;146(Suppl 1):Abstract 1017."},{"key":"B65","series-title":"Hematol Oncol","first-page":"63","article-title":"Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation","volume":"41","author":"Carlo-Stella C","year":"2023","unstructured":"Carlo-Stella C, Hutchings M, Offner F,  Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation. Hematol Oncol 2023;41(Suppl 2):63\u201365."},{"key":"B66","series-title":"J Clin Oncol","first-page":"Abstract 7010","article-title":"Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)","volume":"42","author":"Winter AM","year":"2024","unstructured":"Winter AM, Bharadwaj S, Herrera AF,  Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR). J Clin Oncol 2024;42(Suppl):Abstract 7010."},{"key":"B67","series-title":"J Clin Oncol","first-page":"2071","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an international, multicenter, retrospective study","volume":"42","author":"Kittai AS","year":"2024","unstructured":"Kittai AS, Bond D, Huang Y,  Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an international, multicenter, retrospective study. J Clin Oncol 2024;42:2071\u20132079."},{"key":"B68","series-title":"J Clin Oncol","first-page":"2211","article-title":"Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Cwynarski K","year":"2012","unstructured":"Cwynarski K, van Biezen A, de Wreede L,  Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012;30:2211\u20132217."},{"key":"B69","series-title":"Blood Adv","first-page":"3528","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera AF","year":"2021","unstructured":"Herrera AF, Ahn KW, Litovich C,  Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv 2021;5:3528\u20133539."},{"key":"B70","series-title":"Blood Adv","first-page":"2879","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter\u2019s transformation","volume":"5","author":"Lahoud OB","year":"2021","unstructured":"Lahoud OB, Devlin SM, Maloy MA,  Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter\u2019s transformation. Blood Adv 2021;5:2879\u20132889."},{"key":"B71","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"e35","article-title":"Allogeneic hematopoietic cell transplantation for Richter syndrome: a single-center experience","volume":"18","author":"Kharfan-Dabaja MA","year":"2018","unstructured":"Kharfan-Dabaja MA, Kumar A, Stingo FE,  Allogeneic hematopoietic cell transplantation for Richter syndrome: a single-center experience. Clin Lymphoma Myeloma Leuk 2018;18:e35\u201339."},{"key":"B72","series-title":"Haematologica","first-page":"3219","article-title":"Allogeneic hematopoietic cell transplantation outcomes in patients with Richter\u2019s transformation","volume":"106","author":"Kim HT","year":"2021","unstructured":"Kim HT, Baker PO, Parry E,  Allogeneic hematopoietic cell transplantation outcomes in patients with Richter\u2019s transformation. Haematologica 2021;106:3219\u20133222."},{"key":"B73","series-title":"Am J Hematol","first-page":"E239","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins P","year":"2014","unstructured":"Langerbeins P, Busch R, Anheier N,  Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol 2014;89:E239\u2013243."},{"key":"B74","series-title":"Hematol Oncol","first-page":"Abstract 073","article-title":"Primary endpoint evaluation of a multicenter phase 2 study of venetoclax in combination with R\u2010CHOP (VR-CHOP) for patients with Richter syndrome","volume":"43","author":"Davids MS","year":"2025","unstructured":"Davids MS, Ryan CE, Tyekucheva S,  Primary endpoint evaluation of a multicenter phase 2 study of venetoclax in combination with R\u2010CHOP (VR-CHOP) for patients with Richter syndrome. Hematol Oncol 2025;43(Suppl 3):Abstract 073."},{"key":"B75","series-title":"Br J Haematol","first-page":"259","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers KA","year":"2018","unstructured":"Rogers KA, Huang Y, Ruppert AS,  A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol 2018;180:259\u2013266."},{"key":"B76","series-title":"Cancer","first-page":"1711","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"97","author":"Tsimberidou AM","year":"2003","unstructured":"Tsimberidou AM, Kantarjian HM, Cortes J,  Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97:1711\u20131720."},{"key":"B77","series-title":"J Clin Oncol","first-page":"196","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou AM","year":"2008","unstructured":"Tsimberidou AM, Wierda WG, Plunkett W,  Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196\u2013203."},{"key":"B78","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"568","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou AM","year":"2013","unstructured":"Tsimberidou AM, Wierda WG, Wen S,  Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 2013;13:568\u2013574."},{"key":"B1","series-title":"Proc Natl Acad Sci U S A","first-page":"21194","article-title":"High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment","volume":"108","author":"Logan AC","year":"2011","unstructured":"Logan AC, Gao H, Wang C,  High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A 2011;108:21194\u201321199."},{"key":"B2","series-title":"Leukemia","first-page":"929","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron AC","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A,  A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 2016;30:929\u2013936."},{"key":"B3","series-title":"Leuk Lymphoma","first-page":"1986","article-title":"Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry","volume":"59","author":"Aw A","year":"2018","unstructured":"Aw A, Kim HT, Fernandes SM,  Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. Leuk Lymphoma 2018;59:1986\u20131989."},{"key":"B4","series-title":"Blood","first-page":"1951","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson PA","year":"2019","unstructured":"Thompson PA, Srivastava J, Peterson C,  Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 2019;134:1951\u20131959."},{"key":"B5","series-title":"Leukemia","first-page":"142","article-title":"Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron AC","year":"2013","unstructured":"Rawstron AC, Bottcher S, Letestu R,  Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013;27:142\u2013149."},{"key":"B6","series-title":"Br J Haematol","first-page":"360","article-title":"Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR","volume":"166","author":"Raponi S","year":"2014","unstructured":"Raponi S, Della Starza I, De Propris MS,  Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol 2014;166:360\u2013368."},{"key":"B7","series-title":"Cytometry B Clin Cytom","first-page":"121","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project","volume":"94","author":"Rawstron AC","year":"2018","unstructured":"Rawstron AC, Kreuzer KA, Soosapilla A,  Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom 2018;94:121\u2013128."},{"key":"B8","series-title":"Leukemia","first-page":"3059","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda WG","year":"2021","unstructured":"Wierda WG, Rawstron A, Cymbalista F,  Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia 2021;35:3059\u20133072."},{"key":"B9","series-title":"N Engl J Med","first-page":"1177","article-title":"Measurable residual disease-guided therapy for chronic lymphocytic leukemia","volume":"393","author":"Munir T","year":"2025","unstructured":"Munir T, Girvan S, Cairns DA,  Measurable residual disease-guided therapy for chronic lymphocytic leukemia. N Engl J Med 2025;393:1177\u20131190."},{"key":"B10","series-title":"J Clin Oncol","first-page":"788","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naive chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids MS","year":"2025","unstructured":"Davids MS, Ryan CE, Lampson BL,  Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naive chronic lymphocytic leukemia population enriched for high-risk disease. J Clin Oncol 2025;43:788\u2013799."},{"key":"B11","series-title":"J Clin Oncol","first-page":"2409","article-title":"Zanubrutinib and venetoclax for patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del(17p)\/TP53 mutation: SEQUOIA Arm D results","volume":"43","author":"Shadman M","year":"2025","unstructured":"Shadman M, Munir T, Ma S,  Zanubrutinib and venetoclax for patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del(17p)\/TP53 mutation: SEQUOIA Arm D results. J Clin Oncol 2025;43:2409\u20132417."},{"key":"B12","series-title":"Blood","first-page":"3226","article-title":"Compartment effect on the prognostic significance of MRD detection in CLL: impact of treatment type and duration of follow-up","volume":"128","author":"Rawstron AC","year":"2016","unstructured":"Rawstron AC, Howard D, McParland L,  Compartment effect on the prognostic significance of MRD detection in CLL: impact of treatment type and duration of follow-up. Blood 2016;128:3226."},{"key":"B13","series-title":"Hemasphere","first-page":"e287","article-title":"Minimal residual disease assessment in CLL: ready for use in clinical routine?","volume":"3","author":"F\u00fcrstenau M","year":"2019","unstructured":"F\u00fcrstenau M, De Silva N, Eichhorst B, Hallek M. Minimal residual disease assessment in CLL: ready for use in clinical routine? Hemasphere 2019;3:e287."},{"key":"B14","series-title":"Blood","first-page":"1924","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf O","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C,  Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood 2024;144:1924\u20131935."},{"key":"B15","series-title":"Blood","first-page":"839","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour JF","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF,  Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood 2022;140:839\u2013850."},{"key":"B16","series-title":"J Clin Oncol","first-page":"3689","article-title":"Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib- venetoclax versus chlorambucil-obinutuzumab in the GLOW study","volume":"41","author":"Munir T","year":"2023","unstructured":"Munir T, Moreno C, Owen C,  Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib- venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J Clin Oncol 2023;41:3689\u20133699."},{"key":"B17","series-title":"Blood","first-page":"Abstract 1871","article-title":"First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): GLOW study 64-month follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis","volume":"144","author":"Niemann CU","year":"2024","unstructured":"Niemann CU, Munir T, Owen C,  First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): GLOW study 64-month follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis. Blood 2024;144(Suppl 1):Abstract 1871."},{"key":"B18","series-title":"NEJM Evid","first-page":"EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater AP","year":"2022","unstructured":"Kater AP, Owen C, Moreno C,  Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 2022;1:EVIDoa2200006."},{"key":"B19","series-title":"N Engl J Med.","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","author":"Al-Sawaf O","unstructured":"Al-Sawaf O, Stumpf J, Zhang C,  Fixed-duration versus continuous treatment for chronic lymphocytic leukemia. N Engl J Med. Published online December 6, 2025. doi: 10.1056\/NEJMoa2515458"},{"key":"B20","series-title":"Clin Cancer Res","first-page":"2593","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan JN","year":"2023","unstructured":"Allan JN, Flinn IW, Siddiqi T,  Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia. Clin Cancer Res 2023;29:2593\u20132601."},{"key":"B21","series-title":"J Clin Oncol","first-page":"Abstract 7036","article-title":"Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study","volume":"43","author":"Ghia P","year":"2025","unstructured":"Ghia P, Barr PM, Allan JN,  Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. J Clin Oncol 2025;43(Suppl):Abstract 7036."},{"key":"B22","series-title":"N Engl J Med","first-page":"748","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown JR","year":"2025","unstructured":"Brown JR, Seymour JF, Jurczak W,  Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med 2025;392:748\u2013762."},{"key":"B23","series-title":"Blood","first-page":"Abstract 585","article-title":"IGHV unmutated status, low tumor lysis risk disease and BRAF mutated status are predictors for early MRD responders treated with MRD defined ibrutinib with venetoclax: report of the UK NCRI FLAIR study","volume":"144","author":"Munir T","year":"2024","unstructured":"Munir T, Varghese AM, Bloor A,  IGHV unmutated status, low tumor lysis risk disease and BRAF mutated status are predictors for early MRD responders treated with MRD defined ibrutinib with venetoclax: report of the UK NCRI FLAIR study. Blood 2024;144(Suppl 1):Abstract 585."},{"key":"B24","series-title":"N Engl J Med","first-page":"2517","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach JA","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA,  Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379:2517\u20132528."},{"key":"B25","series-title":"Blood","first-page":"2810","article-title":"Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib","volume":"138","author":"Wang XV","year":"2021","unstructured":"Wang XV, Hanson CA, Tschumper RC,  Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood 2021;138:2810\u20132827."},{"key":"B26","series-title":"Haematologica","first-page":"2108","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno C","year":"2022","unstructured":"Moreno C, Greil R, Demirkan F,  First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica 2022;107:2108\u20132120."},{"key":"B27","series-title":"Leukemia","first-page":"1171","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman JP","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W,  Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia 2022;36:1171\u20131175."},{"key":"B28","series-title":"Blood","first-page":"1276","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman JP","year":"2025","unstructured":"Sharman JP, Egyed M, Jurczak W,  Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood 2025;146:1276\u20131285."},{"key":"B29","series-title":"J Clin Oncol","first-page":"3441","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P,  Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021;39:3441\u20133452."},{"key":"B30","series-title":"N Engl J Med","first-page":"319","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown JR","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P,  Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319\u2013332."},{"key":"B31","series-title":"Lancet Oncol","first-page":"744","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"Furstenau M","year":"2024","unstructured":"Furstenau M, Kater AP, Robrecht S,  First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2024;25:744\u2013759."},{"key":"B32","series-title":"J Clin Oncol","first-page":"2841","article-title":"Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman JP","year":"2025","unstructured":"Sharman JP, Munir T, Grosicki S,  Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol 2025;43:2841\u20132549."},{"key":"B33","series-title":"Blood","first-page":"Abstract 4633","article-title":"Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL\/small lymphocytic lymphoma (SLL): updated follow-up of TRANSCEND CLL 004","volume":"144","author":"Siddiqi T","year":"2024","unstructured":"Siddiqi T, Gauthier J, Kenderian SS,  Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL\/small lymphocytic lymphoma (SLL): updated follow-up of TRANSCEND CLL 004. Blood 2024;144(Suppl 1):Abstract 4633."},{"key":"B34","series-title":"Blood","first-page":"Abstract 887","article-title":"Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): primary results from the open-label, phase 1\/2 Transcend CLL 004 study","volume":"144","author":"Wierda WG","year":"2024","unstructured":"Wierda WG, Dorritie K, Gauthier J,  Lisocabtagene maraleucel (liso-cel) combined with ibrutinib (ibr) for patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): primary results from the open-label, phase 1\/2 Transcend CLL 004 study. Blood 2024;144(Suppl 1):Abstract 887."},{"key":"B35","series-title":"J Clin Oncol","first-page":"2343","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou AM","year":"2006","unstructured":"Tsimberidou AM, O\u2019Brien S, Khouri I,  Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006;24:2343\u20132351."},{"key":"B36","series-title":"Haematologica","first-page":"765","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang Y","year":"2020","unstructured":"Wang Y, Tschautscher MA, Rabe KG,  Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica 2020;105:765\u2013773."},{"key":"B37","series-title":"Leukemia","first-page":"169","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf O","year":"2021","unstructured":"Al-Sawaf O, Robrecht S, Bahlo J,  Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia 2021;35:169\u2013176."},{"key":"B38","series-title":"Ann Hematol","first-page":"2513","article-title":"Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair R","year":"2021","unstructured":"Elnair R, Ellithi M, Kallam A,  Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database. Ann Hematol 2021;100:2513\u20132519."},{"key":"B39","series-title":"Blood Cancer J","first-page":"23","article-title":"Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL","volume":"15","author":"Kittai AS","year":"2025","unstructured":"Kittai AS, Huang Y, Miller S,  Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL. Blood Cancer J 2025;15:23."},{"key":"B40","series-title":"Am J Surg Pathol","first-page":"1605","article-title":"IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao Z","year":"2007","unstructured":"Mao Z, Quintanilla-Martinez L, Raffeld M,  IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 2007;31:1605\u20131614."},{"key":"B41","series-title":"Blood","first-page":"3391","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi D","year":"2011","unstructured":"Rossi D, Spina V, Deambrogi C,  The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117:3391\u20133401."},{"key":"B42","series-title":"Br J Haematol","first-page":"854","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta P","year":"2020","unstructured":"Abrisqueta P, Delgado J, Alcoceba M,  Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol 2020;190:854\u2013863."},{"key":"B43","series-title":"Br J Haematol","first-page":"1016","article-title":"Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome","volume":"198","author":"Favini C","year":"2022","unstructured":"Favini C, Talotta D, Almasri M,  Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. Br J Haematol 2022;198:1016\u20131022."},{"key":"B44","series-title":"Nat Med","first-page":"158","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry EM","year":"2023","unstructured":"Parry EM, Leshchiner I, Guieze R,  Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med 2023;29:158\u2013169."},{"key":"B45","series-title":"Nat Commun","first-page":"309","article-title":"Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis","volume":"14","author":"Broseus J","year":"2023","unstructured":"Broseus J, Hergalant S, Vogt J,  Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis. Nat Commun 2023;14:309."},{"key":"B46","series-title":"Blood Adv","first-page":"2773","article-title":"Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review","volume":"9","author":"Barrett A","year":"2025","unstructured":"Barrett A, Harris C, Eyre TA. Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review. Blood Adv 2025;9:2773\u20132780."},{"key":"B47","series-title":"J Nucl Med","first-page":"1267","article-title":"Detection of Richter\u2019s transformation of chronic lymphocytic leukemia by PET\/CT","volume":"47","author":"Bruzzi JF","year":"2006","unstructured":"Bruzzi JF, Macapinlac H, Tsimberidou AM,  Detection of Richter\u2019s transformation of chronic lymphocytic leukemia by PET\/CT. J Nucl Med 2006;47:1267\u20131273."},{"key":"B48","series-title":"Ann Oncol","first-page":"508","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy A","year":"2009","unstructured":"Noy A, Schoder H, Gonen M,  The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 2009;20:508\u2013512."},{"key":"B49","series-title":"Leuk Lymphoma","first-page":"314","article-title":"2-[18F]fluoro-2-deoxy-D- glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","volume":"55","author":"Papajik T","year":"2014","unstructured":"Papajik T, Myslivecek M, Urbanova R,  2-[18F]fluoro-2-deoxy-D- glucose positron emission tomography\/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. Leuk Lymphoma 2014;55:314\u2013319."},{"key":"B50","series-title":"Blood","first-page":"2783","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi L","year":"2014","unstructured":"Falchi L, Keating MJ, Marom EM,  Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 2014;123:2783\u20132790."},{"key":"B51","series-title":"Leuk Lymphoma","first-page":"1474","article-title":"An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter\u2019s syndrome","volume":"57","author":"Michallet AS","year":"2016","unstructured":"Michallet AS, Sesques P, Rabe KG,  An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter\u2019s syndrome. Leuk Lymphoma 2016;57:1474\u20131477."},{"key":"B52","series-title":"Am J Hematol","first-page":"56","article-title":"Patient characteristics that predict Richter\u2019s transformation in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"98","author":"Kittai AS","year":"2023","unstructured":"Kittai AS, Huang Y, Beckwith KA,  Patient characteristics that predict Richter\u2019s transformation in patients with chronic lymphocytic leukemia treated with ibrutinib. Am J Hematol 2023;98:56\u201365."},{"key":"B53","series-title":"Haematologica","first-page":"2258","article-title":"Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy","volume":"104","author":"Mato AR","year":"2019","unstructured":"Mato AR, Wierda WG, Davids MS,  Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica 2019;104:2258\u20132264."},{"key":"B54","series-title":"Haematologica","first-page":"240564","article-title":"The role of 18F-FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor","volume":"105","author":"Wang Y","year":"2020","unstructured":"Wang Y, Rabe KG, Bold MS,  The role of 18F-FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica 2020;105:240564."},{"key":"B55","series-title":"Blood","first-page":"3419","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding W","year":"2017","unstructured":"Ding W, LaPlant BR, Call TG,  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 2017;129:3419\u20133427."},{"key":"B56","series-title":"Br J Haematol","first-page":"363","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre","volume":"185","author":"Rogers KA","year":"2019","unstructured":"Rogers KA, Huang Y, Dotson E,  Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. Br J Haematol 2019;185:363\u2013366."},{"key":"B57","series-title":"Br J Haematol","first-page":"e117","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand P","year":"2020","unstructured":"Armand P, Murawski N, Molin D,  Pembrolizumab in relapsed or refractory Richter syndrome. Br J Haematol 2020;190:e117\u2013120."},{"key":"B58","series-title":"Blood Adv","first-page":"1958","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain N","year":"2023","unstructured":"Jain N, Senapati J, Thakral B,  A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 2023;7:1958\u20131966."},{"key":"B59","series-title":"J Clin Oncol","first-page":"Abstract 7050","article-title":"Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL)","volume":"42","author":"Wang Y","year":"2024","unstructured":"Wang Y, LaPlant BR, Parikh SA,  Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL). J Clin Oncol 2024;42(Suppl):Abstract 7050."},{"key":"B60","series-title":"Blood","first-page":"Abstract 90","article-title":"Correlates of response to combined checkpoint and BTK inhibition for treatment of Richter transformation: extended follow-up from the prospective RT1 trial","volume":"146","author":"Al-Sawaf O","year":"2025","unstructured":"Al-Sawaf O, Robrecht S, Giza A,  Correlates of response to combined checkpoint and BTK inhibition for treatment of Richter transformation: extended follow-up from the prospective RT1 trial. Blood 2025;146(Suppl 1):Abstract 90."},{"key":"B61","series-title":"Lancet Oncol","first-page":"1298","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi A","year":"2024","unstructured":"Tedeschi A, Frustaci AM, Condoluci A,  Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2024;25:1298\u20131309."},{"key":"B62","series-title":"Lancet Haematol","first-page":"e912","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1\u20132 study","volume":"8","author":"Eyre TA","year":"2021","unstructured":"Eyre TA, Schuh A, Wierda WG,  Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1\u20132 study. Lancet Haematol 2021;8:e912\u2013921."},{"key":"B63","series-title":"Lancet Haematol","first-page":"e682","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study","volume":"11","author":"Wierda WG","year":"2024","unstructured":"Wierda WG, Shah NN, Cheah CY,  Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study. Lancet Haematol 2024;11:e682\u2013692."},{"key":"B64","series-title":"Blood","first-page":"Abstract 1017","article-title":"Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b\/2 EPCORE CLL-1 trial","volume":"146","author":"Kater A","year":"2025","unstructured":"Kater A, Janssens A, Eradat H,  Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b\/2 EPCORE CLL-1 trial. Blood 2025;146(Suppl 1):Abstract 1017."},{"key":"B65","series-title":"Hematol Oncol","first-page":"63","article-title":"Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation","volume":"41","author":"Carlo-Stella C","year":"2023","unstructured":"Carlo-Stella C, Hutchings M, Offner F,  Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation. Hematol Oncol 2023;41(Suppl 2):63\u201365."},{"key":"B66","series-title":"J Clin Oncol","first-page":"Abstract 7010","article-title":"Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)","volume":"42","author":"Winter AM","year":"2024","unstructured":"Winter AM, Bharadwaj S, Herrera AF,  Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR). J Clin Oncol 2024;42(Suppl):Abstract 7010."},{"key":"B67","series-title":"J Clin Oncol","first-page":"2071","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an international, multicenter, retrospective study","volume":"42","author":"Kittai AS","year":"2024","unstructured":"Kittai AS, Bond D, Huang Y,  Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an international, multicenter, retrospective study. J Clin Oncol 2024;42:2071\u20132079."},{"key":"B68","series-title":"J Clin Oncol","first-page":"2211","article-title":"Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Cwynarski K","year":"2012","unstructured":"Cwynarski K, van Biezen A, de Wreede L,  Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter\u2019s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012;30:2211\u20132217."},{"key":"B69","series-title":"Blood Adv","first-page":"3528","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera AF","year":"2021","unstructured":"Herrera AF, Ahn KW, Litovich C,  Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv 2021;5:3528\u20133539."},{"key":"B70","series-title":"Blood Adv","first-page":"2879","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter\u2019s transformation","volume":"5","author":"Lahoud OB","year":"2021","unstructured":"Lahoud OB, Devlin SM, Maloy MA,  Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter\u2019s transformation. Blood Adv 2021;5:2879\u20132889."},{"key":"B71","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"e35","article-title":"Allogeneic hematopoietic cell transplantation for Richter syndrome: a single-center experience","volume":"18","author":"Kharfan-Dabaja MA","year":"2018","unstructured":"Kharfan-Dabaja MA, Kumar A, Stingo FE,  Allogeneic hematopoietic cell transplantation for Richter syndrome: a single-center experience. Clin Lymphoma Myeloma Leuk 2018;18:e35\u201339."},{"key":"B72","series-title":"Haematologica","first-page":"3219","article-title":"Allogeneic hematopoietic cell transplantation outcomes in patients with Richter\u2019s transformation","volume":"106","author":"Kim HT","year":"2021","unstructured":"Kim HT, Baker PO, Parry E,  Allogeneic hematopoietic cell transplantation outcomes in patients with Richter\u2019s transformation. Haematologica 2021;106:3219\u20133222."},{"key":"B73","series-title":"Am J Hematol","first-page":"E239","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins P","year":"2014","unstructured":"Langerbeins P, Busch R, Anheier N,  Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol 2014;89:E239\u2013243."},{"key":"B74","series-title":"Hematol Oncol","first-page":"Abstract 073","article-title":"Primary endpoint evaluation of a multicenter phase 2 study of venetoclax in combination with R\u2010CHOP (VR-CHOP) for patients with Richter syndrome","volume":"43","author":"Davids MS","year":"2025","unstructured":"Davids MS, Ryan CE, Tyekucheva S,  Primary endpoint evaluation of a multicenter phase 2 study of venetoclax in combination with R\u2010CHOP (VR-CHOP) for patients with Richter syndrome. Hematol Oncol 2025;43(Suppl 3):Abstract 073."},{"key":"B75","series-title":"Br J Haematol","first-page":"259","article-title":"A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor","volume":"180","author":"Rogers KA","year":"2018","unstructured":"Rogers KA, Huang Y, Ruppert AS,  A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol 2018;180:259\u2013266."},{"key":"B76","series-title":"Cancer","first-page":"1711","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"97","author":"Tsimberidou AM","year":"2003","unstructured":"Tsimberidou AM, Kantarjian HM, Cortes J,  Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97:1711\u20131720."},{"key":"B77","series-title":"J Clin Oncol","first-page":"196","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou AM","year":"2008","unstructured":"Tsimberidou AM, Wierda WG, Plunkett W,  Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196\u2013203."},{"key":"B78","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"568","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou AM","year":"2013","unstructured":"Tsimberidou AM, Wierda WG, Wen S,  Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 2013;13:568\u2013574."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-p68.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-p68.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-p68.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:35Z","timestamp":1773318695000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-p68.xml"}},"subtitle":["Featured Updates to the NCCN Guidelines"],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":156,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0012","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}